We are a biotech company focused on the discovery and development of novel, fully human monoclonal antibodies for the prevention and treatment of serious bacterial and viral infections in the hospital setting.
In spite of the introduction and evolution of anti-infectives over the past decades, serious bacterial and viral infections continue to cause significant morbidity and mortality in hospitals.
We believe that, based on our MabIgX® technology platform, we are in a position to develop fully human antibodies that specifically address life-threatening infections in the hospital setting.
Our focus is the discovery and development of fully human antibodies that are as close as possible to the antibodies that the human body is producing.
Although Kenta Biotech already has a considerable preclinical portfolio of fully human monoclonal antibodies against several targets, we are striving to expand our portfolio significantly over the next two years. We are focusing on life-threatening diseases with a high medical need.
We want to use our in-depth understanding of immunology as well as our preclinical and clinical in-house experience to provide the market with a superior class of antibodies.
